Global Nanomedicine Market Size, Trends, and Growth Opportunity, By Application (Therapeutics, Active Implants, In-vitro Diagnostics, Drug Delivery, In-vivo Imaging, Implants), By Indication (Clinical Oncology, Infectious diseases, Clinical Cardiology, Orthopedics, Others), By Molecule Type (Nanoparticles, Nano Shells, Nano Tubes, Nano Devices), By Region (North America, Europe, Asia Pacific, Latin America, Middle East) and Forecast till 2030.
Global Nanomedicine Market
The Global Nanomedicine Market was valued at USD 178.4 billion in 2022 and is expected to expand to USD 428.20 billion in 2030 at a CAGR of 10.80 % during the forecast period 2023-2030.
Nanomedicine is a branch of medicine that uses the knowledge of nanotechnology for the prevention, diagnosis, and treatment of disease. it involves the use of nanoscale materials like biocompatible nanoparticles and nanorobots.
Market Drivers
The rising use of nanotechnology-based medication delivery techniques because of advantages in healthcare applications due to the ineffectiveness of traditional therapies in disease treatment and the growing need for safe and cost-effective therapies propel the growth of the market.
The growing advancements in nanotechnology and its applications in preventive interventions, early disease diagnosis, prevention of acute as well as chronic disorders, and prophylaxis of acute as well as chronic disorders act as major factors for the growing market during the forecast period. Furthermore, the increasing production of cutting-edge nano science-based medicines boosts the expansion of the market.
Nanomedicines improve the administration of drugs and disease management and the growing government support and initiatives along with public awareness fuels the market growth.
Market Restraints
The long approval process and risk associated with Nanomedicines as environmental impact hinders the growth of the market.
Furthermore, the high initial cost investment and lack of infrastructure facilities and skilled professionals restrain the growth of the global Nanomedicine market.
COVID-19 Impact on Nanomedicine Market
The outbreak of covid-19 positively impacted the market as nanomedicine is applicable for the prevention, detection, and treatment of viral diseases like the COVID-19 virus. Nanomedicine provides new possibilities for the introduction of innovative solutions to treat novel diseases driven by the market during a pandemic.
Impact of Russia Ukraine War on the Market
The conflict between Russia and Ukraine can have both direct and indirect impacts on the nanomedicine market:
Disruptions in the supply chain: Many Nanomedicine manufacturers source components from Russia and Ukraine. The war may cause supply chain disruptions and delays, affecting nanomedicine production and delivery.
Economic sanctions: Economic sanctions imposed on Russia may have an impact on the overall economy, as well as the demand for nanomedicine in the region.
Market Segmentation
The Global Nanomedicine Market is segmented based on Application, Indication, Molecule Type, and Region. Based on Application, it is segmented into Therapeutics, Active Implants, In-vitro Diagnostics, Drug Delivery, In-vivo Imaging, and Implants. Based on Indication, it is segmented into Clinical Oncology, Infectious diseases, Clinical Cardiology, Orthopedics, and Others. Based on Molecule Type, it is segmented into Nanoparticles, Nano Shells, Nano Tubes, and Nano Devices. Nanoparticles are sub-segmented into Metal & Metal Oxide Nanoparticles, Liposomes, polymer & Polymer Drug Conjugates, Hydrogel Nanoparticles, Dendrimers, and Inorganic Nanoparticles. Based on Region, it is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Regional Analysis
North America is likely to dominate the market over the forecast period owing to the growing number of lethal diseases, increase in demand for nanomedicines, availability of advanced healthcare facilities with skilled professionals, and rising government support in this region.
Asia Pacific is also anticipated to witness substantial growth because of the rising improvement in healthcare infrastructure, and the growing number of hospitals with advanced instruments and technology advancement in this region.
Key Players
Various key players are listed in this report such as Abbott Laboratories, Combi Matrix Corporation, Celgene Corporation, Nano spectra Biosciences Inc, General Electric, Johnson & Johnson Services Inc, Mallinckrodt Pharmaceuticals, Pfizer Inc, Teva Pharmaceutical Industries Ltd, and Arrowhead Pharmaceuticals Inc.
Market Taxonomy
By Application
• Therapeutics
• Active Implants
• In-vitro Diagnostics
• Drug Delivery
• In-vivo Imaging
• Implants
By Indication
• Clinical Oncology
• Infectious diseases
• Clinical Cardiology
• Orthopedics
• Others
By Molecule Type
• Nanoparticles
• Metal & Metal Oxide Nanoparticles
• Liposomes
• Polymers & Polymer Drug Conjugates
• Hydrogel Nanoparticles
• Dendrimers
• Inorganic Nanoparticles
• Nano Shells
• Nano Tubes
• Nano Devices
By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
Key Question Addressed by the Report
• What are the Key Opportunities in Global Nanomedicine Market?
• What will be the growth rate from 2023 to 2030?
• Which segment/region will have the highest growth?
• What are the factors that will impact/drive the Market?
• What is the role of key players in the value chain?
Global Nanomedicine Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Nanomedicine Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing economic downturn
4.2.6 Post covid-19 world Supply& Demand conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Nanomedicine Market, By Indication
5.1 Y-o-Y Growth Comparison, By Indication
5.2 Nanomedicine Market Share Analysis, By Indication
5.3 Nanomedicine Market Size and Forecast, By Indication
5.3.1 Clinical Oncology,
5.3.2 Infectious diseases
5.3.3 Clinical Cardiology
5.3.4 Orthopedics
5.3.5 Others
6 Nanomedicine Market, By Molecule Type
6.1 Y-o-Y Growth Comparison, By Molecule Type
6.2 Nanomedicine Market Share Analysis, By Molecule Type
6.3 Nanomedicine Market Size and Forecast, By Molecule Type
6.3.1 Nanoparticles
6.3.2 Nano Shells
6.3.3 Nano Tubes
6.3.4 Nano Devices
7 Nanomedicine Market, By Application
7.1 Y-o-Y Growth Comparison, By Application
7.2 Nanomedicine Market Share Analysis, By Application
7.3 Nanomedicine Market Size and Forecast, By Application
7.3.1 Therapeutics
7.3.2 Active Implants
7.3.3 In-vitro Diagnostics
7.3.4 Drug Delivery
7.3.5 In-vivo Imaging
7.3.6 Implants
8 Nanomedicine Market, By Region
8.1 Nanomedicine Market Share Analysis, By Region
8.2 Nanomedicine Market Share Analysis, By Region
8.3 Nanomedicine Market Size and Forecast, By Region
9 North America Nanomedicine Market Analysis and Forecast (2023-2030)
9.1 Introduction
9.2 North America Nanomedicine Market Share Analysis, By Indication
9.3 North America Nanomedicine Market Size and Forecast, By Molecule Type
9.4 North America Nanomedicine Market Size and Forecast, By Application
9.5 North America Nanomedicine Market Size and Forecast, By Country
9.5.1 U.S.
9.5.2 Canada
9.5.3 Mexico
10 Europe Nanomedicine Market Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 Europe Nanomedicine Market Share Analysis, By Indication
10.3 Europe Nanomedicine Market Size and Forecast, By Molecule Type
10.4 Europe Nanomedicine Market Size and Forecast, By Application
10.5 Europe Nanomedicine Market Size and Forecast, By Country
10.5.1 Germany
10.5.2 France
10.5.3 UK
10.54. Rest of Europe
11 Asia Pacific Nanomedicine Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Asia Pacific Nanomedicine Market Share Analysis, By Indication
11.3 Asia Pacific Nanomedicine Market Size and Forecast, By Molecule Type
11.4 Asia Pacific Nanomedicine Market Size and Forecast, By Application
11.5 Asia Pacific Nanomedicine Market Size and Forecast, By Country
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4. Rest of Asia Pacific
12 Latin America Nanomedicine Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Latin America Nanomedicine Market Share Analysis, By Indication
12.3 Latin America Nanomedicine Market Size and Forecast, By Molecule Type
12.4 Latin America Nanomedicine Market Size and Forecast, By Application
12.4 Latin America Nanomedicine Market Size and Forecast, Country
12.5.1. Brazil
12.5.2. Rest of Latin America
13 Middle East Nanomedicine Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Middle East Nanomedicine Market Share Analysis, By Indication
13.3 Middle East Nanomedicine Market Size and Forecast, By Molecule Type
13.4 Middle East Nanomedicine Market Size and Forecast, By Application
13.5 Middle East Nanomedicine Market Size and Forecast, By Country
13.5.1. Saudi Arabia
13.5.2. UAE
13.5.3. Egypt
13.5.4. Kuwait
13.5.5. South Africa
14 Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15 Company Profiles
15.1 Abbott Laboratories
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2 Combi Matrix Corporation
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3 Celgene Corporation
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 Nano spectra Biosciences Inc
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 General Electric
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Johnson & Johnson Services Inc
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 Mallinckrodt Pharmaceuticals
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 Pfizer Inc
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 Teva Pharmaceutical Industries Ltd
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 Arrowhead Pharmaceuticals Inc
15.10.1 Overview
15.10.2 Offerings
15.10.3 Key Financials
15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies
